{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:27:46Z","timestamp":1791613666980,"version":"4.3.4"},"reference-count":197,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is the most prevalent malignant monoclonal disease of plasma cells. There is mounting evidence that interactions with the bone marrow (BM) niche are essential for the differentiation, proliferation, survival, migration, and treatment resistance of myeloma cells. For this reason, gaining a deeper comprehension of how BM microenvironment compartments interact with myeloma cells may inspire new therapeutic ideas that enhance patient outcomes. This review will concentrate on the most recent findings regarding the mechanisms of interaction between microenvironment and MM and highlight research on treatment targeting the BM niche.<\/jats:p>","DOI":"10.3389\/fonc.2024.1413494","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:54:57Z","timestamp":1721177697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Ke","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garcia-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.990463","article-title":"Immunotherapy of targeting MDSCs in tumor microenvironment","volume":"13","author":"Sui","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2790-6","article-title":"Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment","volume":"145","author":"Zhou","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7121580","DOI":"10.1155\/2016\/7121580","article-title":"Mesenchymal stem cells and myeloid derived suppressor cells: common traits in immune regulation","volume":"2016","author":"Vladimirovna","year":"2016","journal-title":"J Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400833","article-title":"Noncanonical NF-\u03baB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer","volume":"193","author":"Yu","year":"2014","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.11.002","article-title":"Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway","volume":"442","author":"De Veirman","year":"2019","journal-title":"Cancer Lett"},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-019-1011-5","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation","volume":"18","author":"Ai","year":"2019","journal-title":"Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016980","article-title":"Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK\/ERK MAPK and neutralizing interleukin-6 in progenitor cells","volume":"108","author":"Wang","year":"2006","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","article-title":"Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma","volume":"144","author":"Brimnes","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/s41598-018-23943-w","article-title":"Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy","volume":"8","author":"Shinde","year":"2018","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052136","article-title":"Enhancement of clonogenicity of human multiple myeloma by dendritic cells","volume":"203","author":"Kukreja","year":"2006","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-530964","article-title":"CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma","volume":"123","author":"Murray","year":"2014","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1182\/blood-2019-123333","article-title":"Interaction of plasmacytoid dendritic cells and myeloma cells trigger tumor promoting transcriptional changes in multiple myeloma cells","volume":"134","author":"Ray","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/cells8121526","article-title":"Tumor-associated macrophages in hematologic Malignancies: new insights and targeted therapies","volume":"8","author":"Petty","year":"2019","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2013.12.010","article-title":"Macrophages in multiple myeloma","volume":"161","author":"Ribatti","year":"2014","journal-title":"Immunol Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v5i22","article-title":"Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4\/CXCL12 axis and promote their polarization toward the M2 phenotype","volume":"5","author":"Beider","year":"2014","journal-title":"Oncotarget"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.3390\/cancers14225654","article-title":"Tumor-associated macrophages and related myelomonocytic cells in the tumor microenvironment of multiple myeloma","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18708","article-title":"Single-cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophage-targeted strategy in multiple myeloma","volume":"201","author":"Li","year":"2023","journal-title":"Br J hHaematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-695395","article-title":"Evaluationxxx of xxxthe xxxpotential xxxtherapeutic benefits of macrophage reprogramming in multiple myeloma","volume":"128","author":"Gutierrez-Gonzalez","year":"2016","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i27","article-title":"Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"B34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41419-019-2012-4","article-title":"CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma","volume":"10","author":"Xu","year":"2019","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor-associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma","volume":"24","author":"Gad\u00f3","year":"2000","journal-title":"Cell Biol Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.08.012","article-title":"Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells","volume":"34","author":"Kovacs","year":"2010","journal-title":"Leukemia Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005327","article-title":"Tissue-resident macrophages promote early dissemination of multiple myeloma\u00a0via IL-6 and TNFalpha","volume":"5","author":"Akhmetzyanova","year":"2021","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"J Bone Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210691","article-title":"Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma","volume":"27","author":"Scavelli","year":"2008","journal-title":"Oncogene"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br J cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12032-020-01426-1","article-title":"Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro","volume":"37","author":"Sun","year":"2020","journal-title":"Med Oncol (Northwood London England)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227579","article-title":"Targeting CD47\/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma","volume":"105","author":"Rastgoo","year":"2020","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-015-9921-z","article-title":"Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma","volume":"21","author":"Alexandrakis","year":"2015","journal-title":"Pathol Oncol Res: POR"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101611","DOI":"10.1016\/j.redox.2020.101611","article-title":"Iron regulates myeloma cell\/macrophage interaction and drives resistance to bortezomib","volume":"36","author":"Camiolo","year":"2020","journal-title":"Redox Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/path.4860","article-title":"Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation","volume":"241","author":"De Beule","year":"2017","journal-title":"J Pathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-19-0487","article-title":"Proinflammatory macrophages promote multiple myeloma resistance to bortezomib therapy","volume":"17","author":"Beyar-Katz","year":"2019","journal-title":"Mol Cancer Res: MCR"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.533","article-title":"BAFF is involved in macrophage-induced bortezomib resistance in myeloma","volume":"8","author":"Chen","year":"2017","journal-title":"Cell Death Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-hodgkin's lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0009-3","article-title":"An early history of T cell-mediated cytotoxicity","volume":"18","author":"Golstein","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/leu.2013.310","article-title":"Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma","volume":"28","author":"Atanackovic","year":"2014","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01655","article-title":"Role of tissue-resident memory in intra-tumor heterogeneity and response to immune checkpoint blockade","volume":"9","author":"Dhodapkar","year":"2018","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0220-6","article-title":"Helper T cell differentiation","volume":"16","author":"Saravia","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ncomms1239","article-title":"Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer","volume":"2","author":"Haabeth","year":"2011","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-416792","article-title":"CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis","volume":"120","author":"Brown","year":"2012","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0242-6","article-title":"APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ejh.12481","article-title":"Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro","volume":"95","author":"Frassanito","year":"2015","journal-title":"Eur J Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4(+)PD-1(+) cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090207","article-title":"IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway","volume":"206","author":"Wang","year":"2009","journal-title":"J Exp Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2006.02.012","article-title":"Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma","volume":"17","author":"Alexandrakis","year":"2006","journal-title":"Eur J Intern Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1219","article-title":"Adoptive transfer of tumor-specific th2 cells eradicates tumors by triggering an in situ inflammatory immune response","volume":"76","author":"Lorvik","year":"2016","journal-title":"Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J Immunother (Hagerstown Md: 1997)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.700766","article-title":"Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells","volume":"14","author":"Knight","year":"2012","journal-title":"Cytotherapy"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1038\/s41598-018-22130-1","article-title":"Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma","volume":"8","author":"Gherardin","year":"2018","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.676175","article-title":"The role of natural killer cells in immunity against multiple myeloma","volume":"53","author":"Godfrey","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12082","article-title":"Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy","volume":"139","author":"Costello","year":"2013","journal-title":"Immunology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035981","article-title":"Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent","volume":"7","author":"Feyler","year":"2012","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Cell Mol Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00954","article-title":"Emerging roles of osteoclasts in the modulation of bone microenvironment and immune suppression in multiple myeloma","volume":"8","author":"Mansour","year":"2017","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-\u03b1 blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2684","article-title":"and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.385","article-title":"Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma","volume":"28","author":"Silbermann","year":"2014","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132787","article-title":"Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts","volume":"112","author":"Wakkach","year":"2008","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.04.022","article-title":"Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases","volume":"21","author":"Laperine","year":"2016","journal-title":"Drug Discov Today"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12333","article-title":"Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation","volume":"161","author":"Tucci","year":"2013","journal-title":"Br J Haematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"B94","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11914-007-0006-0","article-title":"Wnt signaling and the regulation of bone mass","volume":"5","author":"Baron","year":"2007","journal-title":"Curr osteoporosis Rep"},{"key":"B95","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.1038\/boneres.2016.9","article-title":"TGF-\u03b2 and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease","volume":"4","author":"Wu","year":"2016","journal-title":"Bone Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237628","article-title":"Osteoclasts are important for bone angiogenesis","volume":"115","author":"Cackowski","year":"2010","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01808-x","article-title":"An IL-1\u03b2-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma","volume":"25","author":"de Jong","year":"2024","journal-title":"Nat Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.1.100","article-title":"In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment","volume":"91","author":"Kim","year":"1998","journal-title":"Blood"},{"key":"B106","article-title":"The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma","volume":"1","author":"Hideshima","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/bjh.14807","article-title":"CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma","volume":"179","author":"Waldschmidt","year":"2017","journal-title":"Br J Haematol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Rep"},{"key":"B109","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/10428190009060320","article-title":"Integrin-mediated drug resistance in multiple myeloma","volume":"38","author":"Damiano","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-292243","article-title":"Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","volume":"117","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206315","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB\/p50) in myeloma cells","volume":"22","author":"Landowski","year":"2003","journal-title":"Oncogene"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4431","article-title":"The activated conformation of integrin beta7 is a novel multiple myeloma-specific target for CAR T cell therapy","volume":"23","author":"Hosen","year":"2017","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204396","article-title":"Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma","volume":"115","author":"Reijmers","year":"2010","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.3390\/ijms20133236","article-title":"Extracellular vesicles enhance multiple myeloma metastatic dissemination","volume":"20","author":"Colombo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B116","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1038\/s41598-017-05002-y","article-title":"Exosomes from metastatic cancer cells transfer amoeboid phenotype to non-metastatic cells and increase endothelial permeability: their emerging role in tumor heterogeneity","volume":"7","author":"Schillaci","year":"2017","journal-title":"Sci Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0788-4","article-title":"piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment","volume":"38","author":"Li","year":"2019","journal-title":"Oncogene"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-018-9649-y","article-title":"Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis","volume":"22","author":"Zarfati","year":"2019","journal-title":"Angiogenesis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v6i15","article-title":"Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation","volume":"6","author":"Raimondi","year":"2015","journal-title":"Oncotarget"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2017.09.001","article-title":"Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior","volume":"65","author":"Bandari","year":"2018","journal-title":"Matrix Biol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41408-018-0139-7","article-title":"Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts","volume":"8","author":"Faict","year":"2018","journal-title":"Blood Cancer J"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0359-0","article-title":"Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"B123","doi-asserted-by":"publisher","first-page":"9012152","DOI":"10.1155\/2017\/9012152","article-title":"Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a","volume":"2017","author":"Cheng","year":"2017","journal-title":"Stem Cells Int"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/path.4712","article-title":"Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression","volume":"239","author":"Wang","year":"2016","journal-title":"J Pathol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01823","article-title":"Cancer cells exploit notch signaling to redefine a supportive cytokine milieu","volume":"9","author":"Colombo","year":"2018","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2016.04.024","article-title":"Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity","volume":"377","author":"De Veirman","year":"2016","journal-title":"Cancer Lett"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000185","article-title":"DCOne as an allogeneic cell-based vaccine for multiple myeloma","volume":"40","author":"Leaf","year":"2017","journal-title":"J Immunother"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00517","article-title":"Immunoglobulin free light chains and GAGs mediate multiple myeloma extracellular vesicles uptake and secondary nfkappaB nuclear translocation","volume":"5","author":"Di Noto","year":"2014","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1279372","article-title":"Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70\/TLR2\/NF-kB axis","volume":"6","author":"Vulpis","year":"2017","journal-title":"Oncoimmunology"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.122","article-title":"The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma","volume":"25","author":"Martin","year":"2011","journal-title":"Leukemia"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2134","article-title":"Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells","volume":"43","author":"Kawano","year":"2013","journal-title":"Int J Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010801","article-title":"Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss","volume":"1","author":"Zahoor","year":"2017","journal-title":"Blood Adv"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-576116","article-title":"Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1","volume":"124","author":"Umezu","year":"2014","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0123","article-title":"Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro","volume":"12","author":"Hu","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-induced CD14+HLA-DR (-\/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma","volume":"2","author":"Noonan","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.46","article-title":"A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib","volume":"28","author":"Ray","year":"2014","journal-title":"Leukemia"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1421760","article-title":"PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise","volume":"59","author":"Ramakrishnan","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2019.05.006","article-title":"Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo","volume":"21","author":"Opperman","year":"2019","journal-title":"Neoplasia (New York NY)"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2017.12.018","article-title":"The good and bad faces of the CXCR4 chemokine receptor","volume":"95","author":"Teixid\u00f3","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"B147","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s42003-020-01441-y","article-title":"Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy","volume":"3","author":"Tu","year":"2020","journal-title":"Commun Biol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-695395","article-title":"Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma","volume":"128","author":"Guti\u00e9rrez-Gonz\u00e1lez","year":"2016","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16158","article-title":"JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression","volume":"188","author":"Chen","year":"2020","journal-title":"Br J Haematol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B152","doi-asserted-by":"publisher","first-page":"100268","DOI":"10.1016\/j.lrr.2021.100268","article-title":"CD47-targeting antibodies as a novel therapeutic strategy in hematologic Malignancies","volume":"16","author":"Sun","year":"2021","journal-title":"Leukemia Res Rep"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br J Haematol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2017","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02204","article-title":"Checkpoint inhibition in myeloma: opportunities and challenges","volume":"9","author":"Costa","year":"2018","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1108","article-title":"Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma","volume":"22","author":"Carlsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"B167","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am J Haematol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 Magnet isMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"B172","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-023-01461-1","article-title":"Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting","volume":"16","author":"Xia","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple m yeloma therapy: latest updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S370880","article-title":"Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives","volume":"16","author":"Shrivastava","year":"2023","journal-title":"OncoTargets Ther"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2113532","article-title":"T cell redirecting bispecific antibodies\u00a0for multiple myeloma: emergin g therapeutic strategies in a changing treatment landscape","volume":"63","author":"Kazandjian","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279760","article-title":"Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration","volume":"117","author":"Moreaux","year":"2011","journal-title":"Blood"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000090","article-title":"Role of osteocytes in multiple myeloma bone disease","volume":"8","author":"Delgado-Calle","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"B178","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05018.x","article-title":"Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation","volume":"126","author":"Lai","year":"2004","journal-title":"Br J Haematol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188882","article-title":"CXCR4 blockade decreases CD4+ T cell exhaustion and improves survival in a murine model of polymicrobial sepsis","volume":"12","author":"Ramonell","year":"2017","journal-title":"PloS One"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4297","article-title":"A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment","volume":"34","author":"Han","year":"2015","journal-title":"Oncol Rep"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.v8i44","article-title":"Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer","volume":"8","author":"Santagata","year":"2017","journal-title":"Oncotarget"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0647","article-title":"A phase ib\/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma","volume":"26","author":"Ghobrial","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0907632","article-title":"Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma","volume":"84","author":"Koldehoff","year":"2008","journal-title":"J Leukoc Biol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1476-4598-9-176","article-title":"Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells","volume":"9","author":"Markovina","year":"2010","journal-title":"Mol Cancer"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-207209","article-title":"Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)","volume":"113","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08623.x","article-title":"Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed\/refractory multiple myeloma: a California Cancer Consortium trial","volume":"154","author":"Somlo","year":"2011","journal-title":"Br J Haematol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27745","article-title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","volume":"119","author":"White","year":"2013","journal-title":"Cancer"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08864.x","article-title":"The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications","volume":"155","author":"Podar","year":"2011","journal-title":"Br J Haematol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgz169","article-title":"Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles","volume":"41","author":"Dabbah","year":"2020","journal-title":"Carcinogenesis"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1325","article-title":"A phase I\/II study of evofosfamide, a hypoxia-activated prodrug with or without bortezomib in subjects with relapsed\/refractory multiple myeloma","volume":"25","author":"Laubach","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1413494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:55:04Z","timestamp":1721177704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1413494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":197,"alternative-id":["10.3389\/fonc.2024.1413494"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1413494","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"article-number":"1413494"}}